|

Sugemalimab Clinical Trials

3 actively recruiting trials

Also known as: Programmed Death Ligand-1 (PD-L1) Inhibitor

Other3 trials

A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC
Phase 3
Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
Phase 1/2
Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT
Phase 2/3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.